title: Mechanisms of incretin effects on plasma lipids and implications for the cardiovascular system.
abstract: Dyslipidemia is a prominent feature of type 2 diabetes and insulin resistance that contributes to increased atherosclerosis and cardiovascular disease (CVD) risks under these conditions. Incretin-based therapies (GLP-1 receptor agonists and DPP-4 inhibitors) have recently been developed and are approved for clinical use for treatment of type 2 diabetes. Besides improved glycemic control, other benefits are being increasingly appreciated, one of which is improved plasma lipid profile. This review aims to summarize the evidence and potential mechanism of such agents in humans in modulating fasting and postprandial lipoprotein metabolism.
authors: Departments of Medicine and Physiology, University of Toronto, Toronto, ON, Canada.
authors: Changting
authors: C
authors: Xiao
authors: Satya
authors: S
authors: Dash
authors: Gary F
authors: GF
authors: Lewis
mesh_terms: D000818:Animals; D002318:Cardiovascular Diseases / Q000097:blood / Q000517:prevention & control; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D054795:Incretins / Q000494:pharmacology*; D007333:Insulin Resistance; D050356:Lipid Metabolism / Q000187:drug effects*; D008055:Lipids / Q000097:blood*; D019518:Postprandial Period; D018027:Receptors, Glucagon / Q000819:agonists* / Q000378:metabolism
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D054795:Incretins; D008055:Lipids; D018027:Receptors, Glucagon